Gilead Sciences Inc. (GILD) Given “Outperform” Rating at Leerink Swann
Leerink Swann reissued their outperform rating on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a report issued on Friday morning. Leerink Swann currently has a $112.00 target price on the biopharmaceutical company’s stock.
Other equities research analysts have also issued research reports about the company. Vetr lowered Gilead Sciences from a strong-buy rating to a buy rating and set a $95.02 price objective on the stock. in a report on Wednesday, July 6th. Credit Suisse Group AG reaffirmed a buy rating and issued a $120.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 29th. Zacks Investment Research raised Gilead Sciences from a hold rating to a buy rating and set a $97.00 price objective on the stock in a report on Monday, July 11th. RBC Capital Markets set a $105.00 price objective on Gilead Sciences and gave the company a buy rating in a report on Thursday, August 11th. Finally, Piper Jaffray Cos. reaffirmed a buy rating and issued a $108.00 price objective on shares of Gilead Sciences in a report on Monday, August 15th. Ten equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $105.00.
Gilead Sciences (NASDAQ:GILD) traded down 2.1016% during midday trading on Friday, hitting $77.4572. The company had a trading volume of 2,164,982 shares. The stock has a market cap of $102.22 billion, a PE ratio of 6.7981 and a beta of 1.10. The stock’s 50-day moving average price is $79.40 and its 200-day moving average price is $85.53. Gilead Sciences has a 52-week low of $76.67 and a 52-week high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same quarter last year, the company posted $3.15 earnings per share. The business’s revenue was down 5.7% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences will post $11.76 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a dividend yield of 2.38%. Gilead Sciences’s payout ratio is currently 16.56%.
In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $84.33, for a total value of $9,444,960.00. Following the sale, the chief executive officer now owns 1,170,963 shares in the company, valued at $98,747,309.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total transaction of $409,200.00. Following the completion of the sale, the executive vice president now owns 132,964 shares in the company, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in the stock. Van Hulzen Asset Management LLC boosted its position in Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares during the period. Joel Isaacson & Co. LLC boosted its position in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 226 shares during the period. Roble Belko & Company Inc boosted its position in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,035 shares during the period. Pinkerton Retirement Specialists LLC boosted its position in Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 1,582 shares during the period. Finally, Jolley Asset Management LLC boosted its position in Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 682 shares during the period. Institutional investors own 77.94% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.